Login to Your Account

Compounded Avastin Recall Good News for Regeneron

By Mari Serebrov
Washington Editor

Wednesday, March 20, 2013

The FDA raised another safety flag over the continued off-label use of Avastin Wednesday when it issued a MedWatch alerting physicians of a recall of the compounded cancer drug intended as an unapproved treatment for wet age-related macular degeneration (AMD).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription